


Stabilis



Morphine tartrate



Noms commerciaux

Morphine tartrate Australie



Stabilité des solutions

| | | 4 mg/ml | 21°C-23°C | | 21 | | | 920 |
|--|--|----------|-----------|--|----|--|--|-----|
| | | 4 mg/ml | 4°C - 8°C | | 21 | | | 920 |
| | | 80 mg/ml | 21°C-23°C | | 21 | | | 920 |
| | | 80 mg/ml | 4°C - 8°C | | 21 | | | 920 |



Stabilité en mélange

| | | 1 mg/ml | 22°C | | Midazolam hydrochloride : 0,5 mg/ml | 28 | | 2083 |
|--|--|------------|------|--|--|----|--|------|
| | | 1 mg/ml | 22°C | | Midazolam hydrochloride : 0,5 mg/ml Bupivacaine hydrochloride : 4 mg/ml | 28 | | 2083 |
| | | 57,8 mg/ml | 21°C | | Ketamine hydrochloride : 27,7 mg/ml | 24 | | 1864 |
| | | 17,6 mg/ml | 21°C | | Ketamine hydrochloride : 41,2 mg/ml | 24 | | 1864 |



Compatibilités

| | |  |  |  |
|---|---|---|--|---|
|  |  | Morphine tartrate Calcium gluconate | | 3644 |
| |  | Morphine tartrate Chlorpromazine hydrochloride | | 519 |
| |  | Morphine tartrate Eptifibatide | | 3934 |
|  |  | Morphine tartrate Fluorouracil | | 3474 |
| |  | Morphine tartrate : 57,8 mg/ml Ketamine hydrochloride : 41,2 mg/ml |  | 1864 |
| |  | Morphine tartrate : 57,8 mg/ml Ketamine hydrochloride : 27,7 mg/ml |  | 1864 |
| |  | Morphine tartrate : 24 mg/ml Ketamine hydrochloride : 10 mg/ml |  | 980 |
|  |  | Morphine tartrate Magnesium sulfate | | 3838 |
| |  | Morphine tartrate Metoclopramide hydrochloride | | 519 |
| |  | Morphine tartrate Morphine sulfate | | 519 |
|  |  | Morphine tartrate Parecoxib sodium | | 3504 |
|  |  | Morphine tartrate Prochlorperazine edysilate | | 519 |
|  |  | Morphine tartrate Thiopental sodium | | 3675 |



Voie d'administration



Bibliographie

| | Type | Source |
|-----|-------|--|
| 519 | Revue | Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 316. |
| 920 | Revue | Targett PL, Keefe PA, Merridew CG. Stability of two concentrations of morphine tartrate in 10 mL polypropylene syringes. Aust J Hosp Pharm 1997 ; 27: 452-454. |
| 980 | Revue | Ambados F. Compatibility of morphine and ketamine for subcutaneous infusion. Aust J Hosp Pharm 1995 ; 25: 352. |

| | | |
|------|-------------|---|
| 1864 | Revue | Lau MH, Hackman C, Morgan DJ. Compatibility of ketamine and morphin injections. Pain 1998 ; 75: 389-390. |
| 2083 | Revue | La Forgia SP, Sharley NA, Burgess NG, Doecke CJ. Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion. J Pharm Pract and Res 2002 ; 32: 65-68. |
| 3474 | Laboratoire | Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
| 3504 | Laboratoire | Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012 |
| 3644 | Laboratoire | Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
| 3675 | Laboratoire | Thiopental sodium - Summary of Product Characteristics Archimedes Pharma UK Ltd 2015 |
| 3838 | Laboratoire | Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007 |
| 3934 | Laboratoire | Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016 |



Dictionnaire

| | |
|--|---|
|  Antalgique |  Injectable |
|  Noms commerciaux |  Stabilité des solutions |
|  Contenant |  Molécule |
|  Concentration |  Température |
|  Conservation |  Durée de stabilité |
|  Biosimilaire |  Données conflictuelles |
|  Bibliographie |  Seringue polypropylène |
|  Chlorure de sodium 0,9% |  A l'abri de la lumière |
|  Jour |  Aucun |
|  Stabilité en mélange |  Solvant |
|  Molécule |  Polyvinyl chlorure |
|  Non précisé |  Lumière |
|  Heure |  Compatibilités |
|  Incompatibilité non précisée |  Incompatible |
|  Compatible |  Instabilité chimique |
|  Voie d'administration |  Intraveineuse |
|  Perfusion intraveineuse |  Perfusion continue |
|  Intramusculaire |  Sous cutanée |
|  Perfusion SC continue |  Bibliographie |
|  Dictionnaire | |